Planep在国内上市没？

Planep (alias: eplerenone, Inspra), approved in the United States in 2002, has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, with fewer adverse reactions and good tolerability. Has Planep been launched in China?

It is understood that Planep was approved for clinical use by the State Food and Drug Administration in 2002, but it has not been officially launched in China!

Patients in need can purchase the version marketed abroad, Planep 50mg × 100 tablets from India's Lupine Pharmaceuticals, which costs about $500. Since exchange rates fluctuate and prices are not fixed, please consult Medical Travel for specific prices. 

The new generation of selective aldosterone antagonist Planep (alias: eplerenone, Inspra) was developed by Pfizer/Pharmacia. The outstanding advantage of Planep is that it can treat severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs. The addition of Planep can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. For patients with severe heart failure and myocardial infarction, Planep combined with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve quality of life and reduce mortality.

Efficacy of Planep (alias: eplerenone, Inspra):

The FDA has approved Planep for use in stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and congestive heart failure after acute myocardial infarction (MI) to improve survival.

Planep is the first aldosterone receptor blocker approved for this indication.

The FDA's approval was based on the results of the EPHESUS (Planep Efficacy and Survival Study in Heart Failure After Acute Myocardial Infarction) trial. In patients with heart failure after myocardial infarction, Planep plus standard treatment reduced mortality by 15% compared with placebo and standard treatment (ACE inhibitors and beta blockers).